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Abstract:  From the dichloromethane/methanol extract of the crinoid Colobometra 
perspinosa, collected south east of Richards Island (Bedara), Family Islands, Central Great 
Barrier Reef, Australia, 3-(1'-hydroxypropyl)-1,6,8-trihydroxy-9,10-anthraquinone [one of 
the two stereoisomers of rhodoptilometrin, (1)], 3-propyl-1,6,8-trihydroxy-9,10-
anthraquinone (3), 2-[(phenylacetyl)amino]ethanesulfonic acid (4), and 4-hydroxybutanoic 
acid (5) were isolated. Comparison of 
1H- and 
13C-NMR data for rhodoptilometrin (1) with 
those reported in the literature showed significant differences for some resonances 
associated with rings A and C. In an attempt to provide accurately assigned 
1H- and   
13C-NMR data, as well as to confirm the structure of 1, a thorough NMR investigation of 
this compound was undertaken. Measurements included: concentration dependent 
13C, 1D 
selective NOE, HSQC, HMBC and 1,1-ADEQUATE. The NMR data for 4 and 5 are 
reported here for the first time, as is their occurrence from the marine environment. The in 
vitro anticancer activity of the original extract was found to be associated with 1, 3 and 5. 
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1. Introduction 
 
Numerous marine organisms are known to produce secondary metabolites as defense mechanisms 
[1–4] which ultimately prove to have other interesting biological activities [5–7]. Many of these 
compounds are brightly coloured. Crinoids are known producers of brightly coloured, typically orange 
red pigments that are predominantly anthraquinoid in nature. The NMR data for these compounds are 
difficult to assign and as a result are often incorrectly assigned [8–10]. NMR techniques that are not 
routinely used need to be applied to resolve assignment issues for this class of compounds [11]. During 
a screening campaign to identify marine extracts with whole cell anticancer activity, a 
dichloromethane/methanol (DCM/MeOH) extract of a specimen of the crinoid Colobometra 
perspinosa, collected from south east of Richards Island (Bedara), Family Islands, Central Great 
Barrier Reef, Australia, was found to be active. Subsequent bioassay and 
1H-NMR guided 
fractionation of the MeOH soluble fraction led to the isolation of compounds 1, 3, 4 and 5. Outlined in 
this publication are details of the structure elucidation of 1, 3, 4 and 5, as well as a detailed discussion 
of the 
13C-NMR data associated with 1 and 3, together with their cytotoxicity, as assessed in a series of 
anticancer cell based assays. 
 
2. Results and Discussion 
 
Rhodoptilometrin (1) was isolated as an orange-yellow microcrystalline solid with a molecular 
weight corresponding to the molecular formula C17H14O6; the molecule had eleven double bond 
equivalents of unsaturation. Analysis of the NMR data for 1 (Table 1) showed it to have 6 × C=C, and 
2 × C=O as the only multiple bonds within the molecule, so 1 was tricyclic. Other structural features of 
the molecule, gleaned from its spectroscopic data, were the presence of two pairs of meta-coupled 
protons and a 1-hydroxypropyl moiety. These deductions indicated 1 to be a tetra-substituted 
anthraquinone, where the substituents were three hydroxyl groups and a 1-hydroxypropyl moiety. 
From 
13C- and 
1H-
13C HMBC data (see Table 1) it was possible to establish the substitution pattern of 
the anthraquinone as shown in Figure 1. Comparison of the NMR data in Table 1 for 1 with those 
reported for rhodoptilometrin (see Table 1 and Table 2) [8–10], raised doubts about the structure, in 
particular the 
13C-NMR resonances for C-4, 5, 6, 8a and 9a, associated with rings A and C of 1, and 
the 
1H-NMR data for H3-3'. If the reported structure of 1 was incorrect, the only other structure that fits 
all of the available data is the regioisomer 2. In an attempt to resolve this regio-chemical issue and 
provide reliable NMR data, a 1,1-ADEQUATE spectrum [11] (see Figure 2 and Table 1), as well as 
13C-NMR spectra at various concentrations (see Table 2), were recorded, and all of the NMR data  
re-examined. There was a slight influence on 
13C-NMR chemical shifts with changing concentration 
(see Table 2), however, nothing to the extent that would account for the differences seen between 
resonances associated with C-4, 5, 6, 8a and 9a reported in the literature [10] and current values. The 
1,1-ADEQUATE cross-peaks observed for 1 between H-4 and C-3, 4, and 4a, between H-2 and C-1 Mar. Drugs 2009, 7      
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and 3, and between H-1' and C-2' and 3, (see Figure 2 and Table 1), coupled with the HMBC cross-
peaks observed between H-4 and C-1, 2, 9 (weak), 9a and 10, defined ring C, the 1-hydroxypropyl 
moiety, and C-10, as shown in 1. Also 1,1-ADEQUATE cross-peaks were observed between H-5 and 
C-6 and 10a, and between H-7 and C-6, together with HMBC cross-peaks observed between H-5 and 
C-6, 7, 8, 8a, 9 (weak) and 10, and between H-7 and C-5, 6, 8, 8a and 9 (weak). This defined ring A 
and C-9, thus completing ring B of the molecule and confirming the planar structure. Based on this 
analysis, the compound isolated in this study was assigned as 1. The specific rotation of 1 measured at 
589 nm was -22, which is in agreement with that reported for rhodoptilometrin by Lee at al. [10]. 
Careful consideration of the C-4, 5, 6, 8a and 9a 
13C-NMR chemical shift differences observed 
between our 1 and that reported by Lee et al. [10], highlighted that, with the exception of C-6, these 
carbons would possibly be influenced by tautomeric effects. This raised the issue of pH and whether 
the compounds were in the same form prior to NMR analysis. In our case, all samples were acid and 
base free prior to measurement as were NMR solvents used for the measurement. Adding formic acid 
or sodium hydroxide to our NMR sample in CD3OD did not alter the chemical shifts of these carbons. 
Compound 1 was also isolated from a more recent collection of Colobometra perspinosa collected 
from Coombe Island in the Family Islands, Central Great Barrier Reef, Australia in 2005. It seems 
likely that the compound isolated and characterized by Lee et al., [10] probably is rhodoptilometrin 
(1), but in the absence of more details concerning isolation and measurement conditions (e.g., 
temperature, concentration and pH) this cannot be stated with certainty. 
Together with rhodoptilometrin (1), 3-propyl-1,6,8-trihydroxy-9,10-anthraquinone (3), or 
dehydroxyrhodoptilometrin, was also isolated and characterized spectroscopically. From comparison 
of the 
1H- and 
13C-NMR data for 1 with that obtained for 3, together with the accurate mass data, it 
was evident that 3 was also a tetra-substituted anthraquinone with three hydroxyl groups and an 
aliphatic moiety at C-3. The differences in the 
1H- and 
13C-NMR chemical shifts of the aliphatic 
substituent between 1 and 3 clearly revealed the presence of a propyl moiety at C-3. For 3, complete 
assignment of 
1H- and 
13C-NMR data are provided for the first time; see Experimental Section and 
Table 1. 
The conjugate of phenylacetic acid and taurine, phenylacetyltaurine, or   
2-[(phenylacetyl)amino]ethanesulfonic acid (4) was also isolated from the MeOH extract. The 
structural elucidation of this molecule was relatively straightforward once the elemental composition 
was determined from accurate mass measurement (C10H12NO4S). It was possible to deduce two 
molecular fragments from the 
1H- and 
13C-NMR data of 4 (see Experimental Section); the phenylacetic 
acid (amide) moiety, an ethyl chain with a terminal nitrogen at C-2, and a heteroatom, unlikely to be 
oxygen or nitrogen, at C-1. With the accurate MS measurement in hand it was evident that the group at 
C-1 was a sulfonic acid and that 4 was the conjugate from the reaction between phenylacetic acid and 
taurine. Surprisingly, this appears to be the first report of this entity as a natural product from the 
marine environment, even though it is encountered fairly often in metabolic studies involving the use 
of phenylacetic acid [12,13]. 
The final compound to be identified in this study was 4-hydroxybutanoic acid or gamma-
hydroxybutyric acid (GHB, 5). The structure elucidation of this molecule was routine. From the   
1H- and 
13C-NMR data of 5 (see Experimental Section), it was evident that the molecule was 
composed of a butyl chain terminating at one end with an OH (C-4, C 68.5 ppm); and at the other with Mar. Drugs 2009, 7      
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a carboxylic acid or amide (C-1, C 177.8 ppm); these deductions were confirmed by routine low 
resolution MS of 5, and showed it to be the free acid and not the amide. The discovery of 5 in a marine 
organism is in itself not surprising, as the molecule is a simple one and commonly found in low 
concentrations in mammals [14]. What does make the discovery interesting is the colourful history 
associated with 5. It is a naturally occurring substance, probably synthesized from gamma-
aminobutyric acid, found in the central nervous system (CNS) of mammals and thought to act as a 
neurotransmitter. It is also found in other organs such as the liver, kidneys, and heart as well as in 
bones. As a drug it is most commonly used in salt form [sodium gamma-hydroxybutyrate (Na-GHB, 
sodium oxybate) or potassium gamma-hydroxybutyrate (K-GHB)], and is used in the treatment of 
insomnia, depression [15], alcoholism [16], historically as an anesthetic, and for sleep disorders [17]. 
Its real notoriety comes from it being represented as a date rape drug, often being referred to as liquid 
ecstasy despite its unrelated effects [18]. 
Compounds 1, 3–5 were screened for their in vitro anti-cancer activity against three human tumour 
cell lines [MCF-7 (breast-pleural effusion adenocarcinoma), SF-268 (CNS-glioblastoma), and H460 
(lung-large cell carcinoma)], the results of which are shown in Table 3. From the bioassay data it can 
be seen that 1, 3 and 5 all demonstrate some non-selective activity towards the three cell lines used for 
the testing, and that functionality in the side chain of 1, compared to 3, appears not to influence this 
activity. The activity observed for 3 is consistent with previous findings for its sulfate derivative [10]. 
Compound 4 appears to be weakly active in only one of the three cell lines (MCF-7). 
Figure 1. Structures of compounds 1–5. 
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Table 1. Comparison of NMR data for 1 isolated in the current study (
1H-NMR at 600 MHz, 
13C-NMR at 150 MHz, basic frequency) with 
that reported previously for 1 [8–10] and with 3. 
  
13C (m)  
1H (m, J Hz)  HMBC (6 Hz)  gHMBC (6 Hz)   1,1-ADEQUATE 
No.  1
a,10  1
a  3
 a  1
a,10  1
a  1
b,9  1
b  1
c,8  1
a,10   1
a   1
a 
1  163.7  (s)  163.6  (s)  163.6  (s)            
2  122.4 (d)  122.3 (d)  124.7 (d)  7.20 (s)  7.24 (d, 1.4)  7.17 (brs)  7.24 (d, 1.4)  6.73 (d, 1.2)  C-4, 1’  C-1’, 1, 3, 4, 9a  C-1, 3 
3  156.1  (s)  156.6  (s)  154.2  (s)            
4
d  116.6 (d)  118.4 (d)  121.2 (d)  7.70 (s)  7.72 (d, 1.4)  7.56 (brs)  7.66 (d, 1.4)  7.16 (d, 1.2)  C-2, 10, 1’  C-1’,  1,  2,  9,  9a, 
10 
C-3, 4a 
4a  135.3  (s)  134.9  (s)  134.7  (s)            
5
d  113.6 (d)  110.4 (d)
  109.1 (d)  7.09 (s)  7.16 (d, 2.4)  6.96 (d, 2.0)  7.02 (d, 2.5)  6.61 (d 2.0)  C-10  C-6, 7, 8, 8a, 9, 10  C-6, 10a 
6
d  160.2 (s)  166.7 (s)
  166.6  (s)            
7  109.7 (d)  109.1 (d)  110.1 (d)  6.35 (d, 3.4)  6.52 (d, 2.4)  6.41 (d 2.0)  6.44 (d, 2.5)  6.02 (d, 2.0)  C-5  C-5, 6, 8, 8a  C-6 
8  167.5  (s)  167.9  (s)  167.2  (s)            
8a
d  113.9  (s)  110.5  (s)  110.5  (s)            
9  192.0  (s)  191.7  (s)  191.9  (s)            
9a
d  118.4  (s)  115.9  (s)  115.0  (s)            
10  184.3  (s)  183.2  (s)  183.2  (s)            
10a  136.9  (s)  136.9  (s)  136.9  (s)            
1'  75.5 (d)  75.4 (d)  39.2 (t)  4.60 (m)  4.62 (t, 6.4)  4.56 (m)  4.57 (t, 6.5)  4.19 (t, 5.8)  C-2, 4  C-2’, 3’, 2, 3, 4  C-2’, 3 
2'  32.6 (t)  32.6 (t)  24.8 (t)  1.73 (m) 1.75  (m) 1.65  (m) 1.63  (m)   C-3, 3’  C-1’, 3’, 3  C-1’, 3’ 
3'
  10.3 (q)  10.2 (q)  14.0 (q)  0.94 (t, 12.5)  0.96 (t, 7.6)  0.91 (t, 8.0)  0.86 (t, 7.3)    C-1’, 2’  C-1’, 2’  C-2’ 
a  Measured in CD3OD, referenced to internal solvent signals ( 3.31 and 49.0 ppm). 
b  Measured in DMSO d6, referenced to internal solvent signals ( 2.50). 
c  Measured in (CD3)2CO, referenced to TMS ( 0). 
d  NMR resonances and coupling constants associated with atoms at these positions are not consistent with the current molecule and the previously reported 
rhodoptilometrin [10] being identical. 
8–10 Data comes from references [8–10], see main text. Mar. Drugs 2009, 7      
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Table 2. 
13C-NMR (600 MHz, CD3OD, 298 K) data for 1 (rhodoptilometrin) at various 
concentrations. 
 
13C (m) for 1 in CD3OD
 conc  mg/600  L
No. Unknown
a  Unknown  32 16 8 4
 
1  163.7 (s)  163.6 (s)  163.4 (s) 163.5 (s)  163.6 (s)  163.7 (s) 
2  122.4 (d)  122.3 (d)  122.2 (d) 122.2 (d)  122.3 (d)  122.3 (d) 
3  156.1 (s)  156.6 (s)  156.5 (s) 156.6 (s)  156.6 (s)  156.7 (s) 
4
b  116.6 (d)  118.4 (d)  118.4 (d) 118.4 (d) 118.4 (d)  118.4 (d)
4a  135.3 (s)  134.9 (s)  134.5 (s) 134.7 (s)  134.8 (s)  134.8 (s) 
5
b  113.6 (d)  110.4 (d) 110.4 (d) 110.4 (d) 110.4 (d)
  110.4 (d)
6
b  160.2 (s)  166.7 (s) 166.4 (s) 166.5 (s ) 166.6 (s)
  166.7 (s)
7  109.7 (d)  109.1 (d)  109.0 (d) 109.0 (d)  109.0 (d)  109.1 (d) 
8  167.5 (s)  167.9 (s)  167.1 (s) 167.2 (s)  167.3 (s)  167.4 (s) 
8a
b  113.9 (s)  110.5 (s)  110.3 (s) 110.4 (s)  110.5 (s)  110.6 (s) 
9  192.0 (s)  191.7 (s)  191.5 (s) 191.7 (s)  191.8 (s)  191.9 (s) 
9a
b  118.4 (s)  115.9 (s)  115.6 (s) 115.7 (s)  115.8 (s)  115.9 (s) 
10  184.3 (s)  183.2 (s)  182.7 (s) 182.9 (s)  183.0 (s)  183.1 (s) 
10a  136.9 (s)  136.9 (s)  136.6 (s) 136.7 (s)  136.9 (s)  137.0 (s) 
1'  75.5 (d)  75.4 (d)  75.4 (d) 75.4 (d)  75.4 (d)  75.4 (d) 
2'  32.6 (t)  32.6 (t)  32.6 (t) 32.6 (t)  32.6 (t)  32.6 (t) 
3'
  10.3 (q)  10.2 (q)  10.2 (q) 10.2 (q)  10.2 (q)  10.2 (q) 
a  Data from reference [10]. 
b  Highlighted rows show ppm values with largest discrepancies from values published in reference [10]. 
 
Table 3. GI50 (M) data for 1, and 3–5 against a series of human tumour cell lines. 
No. SF-268
a MCF-7
b H460
c 
1  41 21 25 
3  72 20 25 
4  >250 195  >250 
5  68 32 50 
a  SF-268 Central nervous system-glioblastoma cells. 
b  MCF-7 Breast-pleural effusion adenocarcinoma cells. 
c  H460 Lung-large cell carcinoma cells. 
 Mar. Drugs 2009, 7      
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Figure 2. 1,1-ADEQUATE spectrum of 1 (600 MHz basic frequency, CD3OD). 
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3. Experimental Section 
 
3.1. General experimental 
 
C18 flash vacuum chromatography was performed using Phenomenex C18 (50 m). HPLC was 
performed with a Shimadzu HPLC system consisting of a Shimadzu SCL-10Avp system controller 
equipped with a Shimadzu LC-10AT pump, Shimadzu SPD-M10Avp photodiode array detector, 
Shimadzu FRC-10A fraction collector and Shimadzu SIL-10A auto sampler. All HPLC data were 
collected using the Shimadzu Class-VP data collection package installed on a Dell Pentium 4 PC 
running Windows 2000. IR spectra were measured on a Nicolet Nexus FTIR. Optical rotations were 
recorded on a Jasco P-1020 polarimeter. All NMR spectra were measured on a Bruker Avance   
600 MHz NMR spectrometer complete with cryoprobe. NMR spectra were referenced to residual 
1H 
and 
13C resonances in the deuterated solvents. Low resolution mass spectral data were measured on a 
Bruker Daltonics Esquire 3000 plus mass spectrometer, complete with Agilent 1100 HPLC system 
comprising of pump, PDA and autosampler. Accurate mass spectrometric data were measured on a 
Bruker BioApex 47 FT mass spectrometer. All other details as previously published [19]. 
 
3.2. Animal material 
 
The original sample of the crinoid Colobometra perspinosa (family Colobometridae), was collected 
from south east of Richards Island (Bedara), Family Islands, Central Great Barrier Reef, Australia, at a 
depth of 12 m, on June the 12
th, 1989 and immediately frozen and stored at -20 °C. A voucher Mar. Drugs 2009, 7      
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specimen is lodged with Queensland Museum, accession number G212468. The sample was collected 
under GBRMPA permit G88/354 and Queensland Fisheries permit 1780. The second collection of the 
crinoid was made from Coombe Island, Family Islands, Central Great Barrier Reef, Australia on  June 
the 27th, 2005 and immediately frozen and stored at -20 °C. A voucher specimen (27124) is lodged at 
AIMS. 
 
3.3. Bioassay 
 
The cell lines SF-268, MCF-7 and H460 were grown in RPMI 1640 medium with L-glutamine 
supplemented with 5% foetal bovine serum and maintained in a humidified incubator at 37 °C with 5% 
CO2. Cells were plated in 96 well microtitre plates at a seeding density of 5,000 cells per well in  
100 L medium and allowed to attach for 24 hours. Natural product samples were solubilised in 
DMSO and serial dilutions prepared in medium. These were added to the cells so that the final doses 
ranged from 250 g/mL to 3 g/mL. The plates were returned to the incubator. Total cellular protein 
was used as an indicator of cell number and was measured at 0 hours and 48 hours after sample 
addition using the sulforhodamine B (SRB) assay. Cells were fixed by addition of 30 L of 50% TCA 
for 30 min at 4 °C, rinsed five times in running water then air dried before staining with 50 L 0.4% 
SRB in 1% acetic acid for 30 mins at room temperature. Plates were washed in five changes of 1% 
acetic acid and air dried. SRB dye was solubilised in 10 mM Tris (100 L) and plates read on a Wallac 
Victor Plate reader with excitation at 540 nm and emission at 590 nm. The concentration at which 
growth was inhibited by 50% (GI50) was determined by comparing the dose response curves of sample 
treated values to those of vehicle only control (100% growth) and Time 0 readings (zero growth). 
Taxol and staurosporine were used as positive controls and medium only and untreated wells were 
used as negative controls. 
 
3.4. Extraction and isolation 
 
The organic solubles (3.37 g of organic extract, obtained employing repeated extraction with 1:1 
DCM-MeOH) obtained from the crinoid were filtered through a plug of reversed phase C18 silica 
using MeOH as eluent. The MeOH was removed under reduced pressure and the resultant filtrate 
subjected to preparative RP-HPLC (9.5 mL/min, gradient elution from 10% MeCN:H2O (+0.1% 
formic acid) to MeCN (+0.1% formic acid); column 250 × 20 mm RP Luna C18 (2), Phenomenex) 
over 80 mins, to yield 34 fractions. Of the 34 fractions two, fractions 16 and 17, were found to be 
active in the bioassay. 
1H-NMR analysis of all fractions showed fractions 9–11 to be 4 (16.7 mg, 0.5% 
organic extract), fractions 16 and 17 to be 1 (75.3 mg, 2.2% organic extract), fraction 24 to be 3  
(9.5 mg, 0.3% organic extract), and fraction 34 to be 5 (27.7 mg, 0.8% organic extract). 
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3.5. 3-(1’-Hydroxypropyl)-1,6,8-trihydroxy-9,10-anthraquinone (Rhodoptilometrin, 1) 
 
An orange-yellow microcrystalline solid. []
20
D -22 (c 0.1, MeOH); IR (film) max 3420, 1660,  
1280 cm
-1; UV (PDA, MeOH) max 512 nm; 
1H- (600 MHz, CD3OD), and 
13C- (150 MHz, CD3OD) 
NMR data see Table 1; HRESIMS m/z found 313.0710 for [M-H]
- (calcd for C17H13O6 313.0712). 
 
3.6. 3-Propyl-1,6,8-trihydroxy-9,10-anthraquinone (3) 
 
An orange-yellow optically inactive powder. IR (film) max 3420, 1660, 1280 cm
-1; UV (PDA, 
MeOH)  max 512 nm; 
1H-NMR (600 MHz, CD3OD)   7.58 (1H, H-4, brs), 7.18 (1H, H-5, d,   
J = 2.3 Hz), 7.10 (1H, H-2, brs), 6.56 (1H, H-7, d, J = 2.3 Hz), 2.69 (2H, H-1', t, J = 7.3 Hz), 1.71 (2H, 
H-2', sep, J = 7.3 Hz), 0.99 (3H, H-3', t, J = 7.3 Hz); 
13C-NMR (150 MHz, CD3OD) see Tables 1 and 
2; HRESIMS m/z found 297.0782 for [M-H]
- (calcd for C17H13O5 297.0802). 
 
3.7. 4-[(Phenylacetyl)amino]ethanesulfonic acid (4) 
 
A colourless optically inactive oil. 
1H-NMR (600 MHz, DMSO-d6)  2.53 (H2-1, brt, J = 7.3 Hz), 
3.29 (H2-2, dt, J = 5.6, 7.3 Hz), 3.37 (H2-4, s), 7.21 (H-8, t, J = 7.5 Hz), 7.24 (2H, H-6 and H-10, d,  
J = 7.5 Hz), 7.28 (2H, H-7 and H-9, t, J = 7.5 Hz); 
13C-NMR (150 MHz, DMSO-d6)  35.7 (t, C-2), 
42.5 (t, C-4), 50.6 (t, C-1), 126.3 (s, C-8), 128.2 (2 × d, C-6, 10), 129.0 (2 × d, C-7, 9), 136.4 (s, C-5), 
169.7 (s, C-3); HRESIMS m/z found 242.0493 for [M-H]
- (calcd for C10H12NO4S 242.0487). 
 
3.8. 4-Hydroxybutanoic acid (5) 
 
A colourless optically inactive oil. 
1H (600 MHz, CDCl3)  4.35 (2H, H-4, t, J = 7.2 Hz), 2.50 (2H, 
H-2, t, J = 8.1 Hz), 2.26 (2H, H-3, tt, J = 7.2, 8.1 Hz); 
13C (150 MHz, CDCl3)  177.8 (s, C-1), 68.5 (t,  
C-4), 27.8 (t, C-2), 22.1 (t, C-3); ESIMS m/z 103 [M-H]
-, 85 [M-H2O]
-. 
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